Brief: Gt Biopharma Presents Preclinical Data Demonstrating Second-Generation Cd19 Targeting Tri-Specific Killer Engager Driving Robust Nk Cell Function Against B Cell Malignancies
10/06/2022 13:09
June 10 (Reuters) - GT Biopharma Inc GTBP.O :
* GT BIOPHARMA PRESENTS PRECLINICAL DATA DEMONSTRATING
SECOND-GENERATION CD19 TARGETING TRI-SPECIFIC KILLER ENGAGER
(TRIKE®) DRIVING ROBUST NK CELL FUNCTION AGAINST B CELL
MALIGNANCIES AT EHA 2022 CONGRESS
* GT BIOPHARMA INC - ONGOING EXPERIMENTS WILL EVALUATE
FUNCTIONALITY AND EFFICACY OF GTB-7550 IN VIVO
* GT BIOPHARMA INC - FUTURE STUDIES WILL ALSO INVOLVE
ASSESSMENTS
OF GTB-7550 TRIKE EFFICACY IN OTHER HEMATOLOGIC CANCERS
Source text for Eikon: ID:nGNXbFFxGl
Further company coverage: GTBP.O
((reuters.briefs@thomsonreuters.com;))